Radiotherapy for ocular tumours

Stannard, Clare; Sauerwein, W.; Maree, G.J.; Lecuona, Karin

doi:10.1038/eye.2012.241

Cited by 104 publications

(84 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, the majority of the patients received brachytherapy that is highly localized. 48 The second most common modality was beam irradiation, which most likely represents proton beam irradiation for most tumors. Owing to the Bragg peak effect, proton beam irradiation-charged particles also have minimal scatter and deliver the maximum dose at the end of their range, 49 resulting in no radiation exposure to tissues outside the orbit.…”

Section: Study Populationmentioning

confidence: 99%

Second Primary Neoplasms in Patients With Uveal Melanoma: A SEER Database Analysis

Bartosch

Mondim

Healy

et al. 2016

American Journal of Ophthalmology

View full text Add to dashboard Cite

PURPOSE: To determine the risk of second primary neoplasms (SPNs) in subjects previously diagnosed with uveal melanoma (UM), including an analysis on whether radiotherapy is a risk factor to develop these SPNs.DESIGN: Retrospective cohort study. METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) 9 database, we identified patients diagnosed with UM as their first malignancy between 1973 and 2011 (n [ 3976). We obtained standardized incidence ratios (SIR) and excess absolute risks of SPNs on patients with UM compared to a reference population. Multivariate Cox regression models were used to evaluate the effect of radiotherapy in SPN risk.RESULTS: Sixteen percent (n [ 641) of the patients developed SPNs during a median follow-up of 83 months (range, 1-463 months). This represented an 11% excess risk compared to the reference population, mainly owing to a significantly increased risk of skin melanomas (SIR [ 2.93, 95% CI: 2.23-3.78) and kidney tumors (SIR [ 1.91, 95% CI: 1.27-2.76), primarily in those diagnosed between 30 and 59 years of age. The occurrence of second UM was also increased (SIR [ 16.90, 95% CI: 9.00-28.90), which likely includes recurrences misclassified as a second cancer. Radiotherapy was performed in 39% (n [ 1538) of the patients. Multivariate analysis revealed that this treatment was not an independent risk factor for SPNs (hazard ratio [ 1.06, 95% CI: 0.88-1.26, P [ .54).CONCLUSIONS: Patients with UM presented an 11% higher risk of SPNs compared to the reference population. Radiotherapy does not seem to be a risk factor. SPNs should be considered in the surveillance of UM. (Am J Ophthalmol 2016;165:54-64. Ó 2016 Elsevier Inc. All rights reserved.) P UBLISHED DATA ON SURVIVAL OF UVEAL MELAnoma demonstrate that more than half of the patients are long-term survivors. At 5 and 10 years, the survival rates range between 68%-82% and 57%-62%, respectively.

show abstract

Section: Study Populationmentioning

confidence: 99%

Second Primary Neoplasms in Patients With Uveal Melanoma: A SEER Database Analysis

Bartosch

Mondim

Healy

et al. 2016

American Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Such a bolus increases skin dose, homogenizes dose heterogeneity resulting from the irregular skin surface, and protects distal tissues by conforming dose line to the distal PTV surface 9. Similarly, bolus electron conformal therapy (ECT) has been shown clinically useful for many clinical sites10 such as chest wall irradiation (postmastectomy irradiation),11, 12, 13 head and neck radiotherapy,14, 15, 16, 17, 18, 19, 20, 21, 22, 23 paraspinal muscle region,24 and extremities 25…”

Section: Introductionmentioning

confidence: 99%

Utilization of a 3D printer to fabricate boluses used for electron therapy of skin lesions of the eye canthi

Łukowiak

Jezierska

Boehlke

et al. 2016

J Applied Clin Med Phys

View full text Add to dashboard Cite

This work describes the use of 3D printing technology to create individualized boluses for patients treated with electron beam therapy for skin lesions of the eye canthi. It aimed to demonstrate the effectiveness of 3D‐printed over manually fabricated paraffin boluses. The study involved 11 patients for whom the construction of individual boluses were required. CT scans of the fabricated 3D‐printed boluses and paraffin boluses were acquired and superimposed onto patient CT scans to compare their fitting, bolus homogeneity, and underlying dose distribution. To quantify the level of matching, multiple metrics were utilized. Matching Level Index (ML) values ranged from 0 to 100%, where 100% indicated a perfect fit between the reference bolus (planned in treatment planning system) and 3D‐printed and paraffin bolus. The average ML (± 1 SD) of the 3D‐printed boluses was 95.1 ± 2.1%, compared to 46.0 ± 10.1% for the manually fabricated paraffin bolus. Correspondingly, mean doses were closer to the prescribed doses, and dose spreads were less for the dose distributions from the 3D‐printed boluses, as compared to those for the manually fabricated paraffin boluses. It was concluded that 3D‐printing technology is a viable method for fabricating boluses for small eye lesions and provides boluses superior to our boluses manually fabricated from paraffin sheets.

show abstract

“…1 MMC, 5-fluorouracil, interferon, 2 and radiotherapy (including external beam radiotherapy and brachytherapy) 3 have been used as adjuvant treatment with variable success rates.…”

Section: Commentmentioning

confidence: 99%

Treatment of invasive ocular surface squamous neoplasia with proton beam therapy

El-Assal

Salvi

Rundle

et al. 2013

Eye

View full text Add to dashboard Cite

Sir, Treatment of invasive ocular surface squamous neoplasia with proton beam therapy Ocular surface squamous neoplasia (OSSN) has the potential for causing significant ocular and systemic morbidity and mortality. We present two cases of invasive OSSN successfully treated with proton beam therapy (PBT). Both were non-resectable due to deeper scleral invasion. Case reports Case 1A 73-year-old patient was referred to the Ocular Oncology Service with a nodular lesion in the lower fornix (Figure 1a). Incisional biopsy revealed widespread carcinoma in situ with invasive focus (Figures 1c and d). Four cycles of topical MytomycinC (MMC, 0.02%) were administered; however, tumour growth continued.

show abstract

Radiotherapy for ocular tumours

Cited by 104 publications

References 39 publications

Second Primary Neoplasms in Patients With Uveal Melanoma: A SEER Database Analysis

Second Primary Neoplasms in Patients With Uveal Melanoma: A SEER Database Analysis

Utilization of a 3D printer to fabricate boluses used for electron therapy of skin lesions of the eye canthi

Treatment of invasive ocular surface squamous neoplasia with proton beam therapy

Contact Info

Product

Resources

About